MGI PHARMA licenses North American rights to MG98 and a complementary small molecule DNA methyltransferase inhibitor program from Methylgene, Inc. The Company also expands its portfolio of marketed products by purchasing the worldwide rights to Hexalen® Capsules, allowing the MGI PHARMA commercial organization to expand its oncology focus.